Royalty Pharma PLC reports results for the quarter ended in March - Earnings Summary

Royalty Pharma

09/05/2024 14:53

* Royalty Pharma PLC  RPRX.OQ  reported quarterly adjusted
earnings of 98 cents​​ per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of $1.60.  The mean expectation of five analysts for the
quarter was for earnings of 98 cents per share. Wall Street
expected results to range from 91 cents to $1.07 per share.
    * Revenue fell 20.8% to $542.00 million from a year ago;
analysts
expected $663.22 million. 
    * Royalty Pharma PLC's reported EPS for the quarter was 1
cent​.
    * The company reported quarterly net income of $5 million.
    * Royalty Pharma PLC shares had fallen by 7.8% this
quarter and
lost 0.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Royalty Pharma
PLC is $44.00 
This summary was machine generated from LSEG data May 9 at 01:53
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      0.98           0.98           Met
 Dec. 31 2023      1.01           1.15           Beat
 Sep. 30 2023      0.76           0.79           Beat
 Jun. 30 2023      0.81           0.84           Beat